These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34427069)

  • 1. Time-Course Changes in Bone Metabolism Markers and Density in Patients with Osteoporosis Treated with Romosozumab: A Multicenter Retrospective Study.
    Inage K; Orita S; Eguchi Y; Shiga Y; Koda M; Aoki Y; Kotani T; Akazawa T; Furuya T; Nakamura J; Takahashi H; Suzuki-Narita M; Maki S; Hagiwara S; Inoue M; Norimoto M; Kinoshita H; Sato T; Sato M; Enomoto K; Takaoka H; Mizuki N; Hozumi T; Tsuchiya R; Kim G; Otagiri T; Mukaihata T; Hishiya T; Ohtori S
    Yonsei Med J; 2021 Sep; 62(9):829-835. PubMed ID: 34427069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study.
    Tominaga A; Wada K; Kato Y; Nishi H; Terayama Y; Okazaki K
    Osteoporos Int; 2021 Apr; 32(4):653-661. PubMed ID: 32979066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effects, safety, and predictors of the effectiveness of romosozumab in primary and secondary osteoporosis: An observational study.
    Mineta K; Nishisho T; Okada M; Kamada M; Sairyo K
    Bone; 2024 Sep; 186():117164. PubMed ID: 38871265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.
    Hu M; Zhang Y; Guo J; Guo C; Yang X; Ma X; Xu H; Xiang S
    Front Endocrinol (Lausanne); 2023; 14():1188969. PubMed ID: 37529613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study.
    Sato M; Inaba M; Yamada S; Emoto M; Ohno Y; Tsujimoto Y
    J Bone Miner Metab; 2021 Nov; 39(6):1082-1090. PubMed ID: 34324082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration.
    Kobayakawa T; Miyazaki A; Kanayama Y; Hirano Y; Takahashi J; Suzuki T; Nakamura Y
    Mod Rheumatol; 2023 Jan; 33(1):96-103. PubMed ID: 35234889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis.
    Graeff C; Campbell GM; Peña J; Borggrefe J; Padhi D; Kaufman A; Chang S; Libanati C; Glüer CC
    Bone; 2015 Dec; 81():364-369. PubMed ID: 26232375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Kato Y
    Osteoporos Int; 2021 Oct; 32(10):1999-2009. PubMed ID: 33770201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
    Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
    J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR; Grauer A; Boonen S; Bolognese MA; Brown JP; Diez-Perez A; Langdahl BL; Reginster JY; Zanchetta JR; Wasserman SM; Katz L; Maddox J; Yang YC; Libanati C; Bone HG
    N Engl J Med; 2014 Jan; 370(5):412-20. PubMed ID: 24382002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Real-World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study.
    Inose H; Ariga A; Motoyoshi T; Fukushima K; Tomizawa S; Kato T; Takahashi K; Yoshii T; Okawa A
    JBMR Plus; 2022 Jul; 6(7):e10637. PubMed ID: 35866147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonresponder Considerations for Romosozumab Treatment.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Shimamoto S; Kodama Y; Kato Y
    Calcif Tissue Int; 2023 Aug; 113(2):157-165. PubMed ID: 37138124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
    Lewiecki EM; Blicharski T; Goemaere S; Lippuner K; Meisner PD; Miller PD; Miyauchi A; Maddox J; Chen L; Horlait S
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3183-3193. PubMed ID: 29931216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
    Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Hirao M; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Okamura G; Etani Y; Takami K; Goshima A; Nakata K
    Bone; 2020 Nov; 140():115574. PubMed ID: 32777516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study.
    Kobayakawa T; Suzuki T; Nakano M; Saito M; Miyazaki A; Takahashi J; Nakamura Y
    Bone Rep; 2021 Jun; 14():101068. PubMed ID: 33981812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.
    Chavassieux P; Chapurlat R; Portero-Muzy N; Roux JP; Garcia P; Brown JP; Libanati C; Boyce RW; Wang A; Grauer A
    J Bone Miner Res; 2019 Sep; 34(9):1597-1608. PubMed ID: 31233639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
    Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis.
    Nealy KL; Harris KB
    Ann Pharmacother; 2021 May; 55(5):677-686. PubMed ID: 32862655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.